Luminescent and Optical Thin Film Coatings in Ophthalmic Lenses: Advances, Clinical Applications, and Future Directions

Ophthalmic lens coatings are increasingly designed to combine optical, mechanical, and biological functions. This systematic review, registered in PROSPERO and conducted according to PRISMA 2020 guidelines, synthesized 54 experimental, preclinical, and clinical studies on coatings for spectacle lenses, contact lenses, and intraocular lenses. Spectacle lens studies consistently showed that anti-reflective and blue-light filtering coatings reduce glare perception, improve contrast sensitivity, and provide UV protection, while laboratory tests demonstrated significant reductions in impact resistance, with fracture energy of CR-39 lenses decreasing by up to 63% when coated. Contact lens research revealed that plasma and polymeric coatings reduce water contact angles from >100° to <20°, enhancing wettability, while antimicrobial strategies such as melamine binding or nanoparticle-based films achieved >80% reductions in bacterial adhesion. Drug-eluting approaches sustained antibiotic or antioxidant release for periods ranging from 24 h to 6 days, with improved ocular bioavailability compared with drops. Intraocular lens studies demonstrated that heparin surface modifications reduced postoperative flare and anterior chamber cells, and phosphorylcholine or alkylphosphocholine coatings suppressed lens epithelial cell proliferation. Drug-loaded coatings with methotrexate, gefitinib, or amikacin significantly inhibited posterior capsule opacification and infection in ex vivo and animal models. Collectively, coatings improve visual comfort, photoprotection, wettability, and biocompatibility, but clinical translation requires solutions to mechanical trade-offs, long-term stability, and regulatory challenges.